Jishnu Malgie, Mariëlle I Wilde, Pascal R D Clephas, Mireille E Emans, Stefan Koudstaal, Jeroen Schaap, Arend Mosterd, Jan van Ramshorst, Alexander J Wardeh, Sandra van Wijk, Mieke van den Heuvel, Eric Wierda, C Jan Willem Borleffs, Colette Saraber, Saskia L M A Beeres, Roland van Kimmenade, Wouter Jansen Klomp, Robert Denham, Carlos A da Fonseca, IJsbrand T Klip, Olivier C Manintveld, Robert M A van der Boon, Clara E E van Ofwegen, Ayten Yilmaz, Ron Pisters, Gerard C M Linssen, Nikola Faber, Loek van Heerebeek, Julio E C van de Swaluw, Lex J Bouhuijzen, Marco C Post, Aaf F M Kuijper, Ka Wai Wu, Eugène A van Beek, Tim Hesselink, Lennaert Kleijn, Maurice J M Kurvers, René A Tio, Jorina Langerveld, Bas M van Dalen, J W Martijn van Eck, M Louis Handoko, Walter R M Hermans, Hetty J J Koornstra-Wortel, Mariusz K Szymanski, Dennis Rooker, Kenneth Tandjung, Sabine C M Eijsbouts, Folkert W Asselbergs, Peter van der Meer, Hans-Peter Brunner-La Rocca, Rudolf A de Boer, Jasper J Brugts
AIMS: Despite clear guideline recommendations for initiating four drug classes in all patients with heart failure (HF) with reduced ejection fraction (HFrEF) and the availability of rapid titration schemes, information on real-world implementation lags behind. Closely following the 2021 ESC HF guidelines and 2023 focused update, the TITRATE-HF study started to prospectively investigate the use, sequencing, and titration of guideline-directed medical therapy (GDMT) in HF patients, including the identification of implementation barriers...
May 12, 2024: European Journal of Heart Failure